drugset
drugset / Trial / NCT02972645

A Study of LY3305677 in Healthy Participants

NCT02972645 ↗

Phase 1 Completed 66 enrolled Eli Lilly and Company
RandomizedSingle-groupDouble-blindBasic science

Summary

The purpose of this study is to evaluate the safety of LY3305677 and any side effects that might be associated with it. This study will also look at how much LY3305677 gets into the blood stream, how long it takes the body to remove it. This study involves a single dose of LY3305677 administered by subcutaneous injection (SC). Participation in this study is expected to last up to 16 weeks.

Timeline

Start
2016-12-05
Primary completion
2017-07-14
Completion
2017-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Mazdutide Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.